PEG-modified biopharmaceuticals
PEGylation is a process in which one or more units of chemically activated polyethylene glycol reacts with a biomolecule, usually a protein, peptide, small molecule or oligonucleotide, creating a putative new molecular entity possessing physicochemical and physiological characteristics that are dist...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on drug delivery 2009-01, Vol.6 (1), p.1-16 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Expert opinion on drug delivery |
| container_volume | 6 |
| creator | Bailon, Pascal Won, Chee-Youb |
| description | PEGylation is a process in which one or more units of chemically activated polyethylene glycol reacts with a biomolecule, usually a protein, peptide, small molecule or oligonucleotide, creating a putative new molecular entity possessing physicochemical and physiological characteristics that are distinct from its predecessor molecules. In recent years, PEGylation has been used not only as a drug delivery technology but used also as a drug modification technology to transform existing biopharmaceuticals clinically more efficacious than before their PEGylation. PEGylation bestows several useful properties upon the native molecule, resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native molecule to achieve maximum clinical potency. In addition, PEGylation results in sustained clinical response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost. During the course of development of various pegylated protein therapeutics, several new insights have been gained. This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics. |
| doi_str_mv | 10.1517/17425240802650568 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_19236204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66960046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-2b366db89bced8d63cc10f40d4c2b1961bfef59fd32f41cb214ad9ff863a091c3</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMotl4ewI26cjea-8ygGym1CgVd6DrkSlNmJjWZQfr2RlsQEerqHA7f_3P4ADhD8BoxVN6gkmKGKawg5gwyXu2Bcb7RomQ12f_ecZGBcgSOUlpCSHgJ0SEYoRoTjiEdg4uX6axog_HOW3OpfFgtZGyltkPvtWzSCThwedjT7TwGbw_T18ljMX-ePU3u54WmhPUFVoRzo6paaWsqw4nWCDoKDdVYoZoj5axjtTMEO4q0wohKUztXcSJhjTQ5Bleb3lUM74NNvWh90rZpZGfDkATnNYeQ8n9BDAlDnNEMog2oY0gpWidW0bcyrgWC4kuf-KMvZ8635YNqrflJbH1l4G4D-M6F7OkjxMaIXq6bEF2UnfZJkF39t7_iCyubfqFltGIZhthlwzu--wSkDI5e</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20351654</pqid></control><display><type>article</type><title>PEG-modified biopharmaceuticals</title><source>MEDLINE</source><source>Taylor & Francis Online</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Bailon, Pascal ; Won, Chee-Youb</creator><creatorcontrib>Bailon, Pascal ; Won, Chee-Youb</creatorcontrib><description>PEGylation is a process in which one or more units of chemically activated polyethylene glycol reacts with a biomolecule, usually a protein, peptide, small molecule or oligonucleotide, creating a putative new molecular entity possessing physicochemical and physiological characteristics that are distinct from its predecessor molecules. In recent years, PEGylation has been used not only as a drug delivery technology but used also as a drug modification technology to transform existing biopharmaceuticals clinically more efficacious than before their PEGylation. PEGylation bestows several useful properties upon the native molecule, resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native molecule to achieve maximum clinical potency. In addition, PEGylation results in sustained clinical response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost. During the course of development of various pegylated protein therapeutics, several new insights have been gained. This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</description><identifier>ISSN: 1742-5247</identifier><identifier>EISSN: 1744-7593</identifier><identifier>EISSN: 1743-5247</identifier><identifier>DOI: 10.1517/17425240802650568</identifier><identifier>PMID: 19236204</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>biopharmaceuticals ; biosimilar ; Chemistry, Pharmaceutical - methods ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Delivery Systems ; EPR ; Humans ; Medication Adherence ; NME ; PEG ; PEG-biosimilar ; PEG-linkers ; PEGylation ; Peptides - administration & dosage ; Peptides - chemistry ; Peptides - pharmacokinetics ; pharmacokinetics renal clearance ; poly(ethylene glycol) ; Polyethylene Glycols - chemistry ; Proteins - administration & dosage ; Proteins - chemistry ; Proteins - pharmacokinetics ; putative ; tumor-targeting</subject><ispartof>Expert opinion on drug delivery, 2009-01, Vol.6 (1), p.1-16</ispartof><rights>Informa UK Ltd 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-2b366db89bced8d63cc10f40d4c2b1961bfef59fd32f41cb214ad9ff863a091c3</citedby><cites>FETCH-LOGICAL-c435t-2b366db89bced8d63cc10f40d4c2b1961bfef59fd32f41cb214ad9ff863a091c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/17425240802650568$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/17425240802650568$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,59623,59729,60412,60518</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19236204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bailon, Pascal</creatorcontrib><creatorcontrib>Won, Chee-Youb</creatorcontrib><title>PEG-modified biopharmaceuticals</title><title>Expert opinion on drug delivery</title><addtitle>Expert Opin Drug Deliv</addtitle><description>PEGylation is a process in which one or more units of chemically activated polyethylene glycol reacts with a biomolecule, usually a protein, peptide, small molecule or oligonucleotide, creating a putative new molecular entity possessing physicochemical and physiological characteristics that are distinct from its predecessor molecules. In recent years, PEGylation has been used not only as a drug delivery technology but used also as a drug modification technology to transform existing biopharmaceuticals clinically more efficacious than before their PEGylation. PEGylation bestows several useful properties upon the native molecule, resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native molecule to achieve maximum clinical potency. In addition, PEGylation results in sustained clinical response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost. During the course of development of various pegylated protein therapeutics, several new insights have been gained. This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</description><subject>biopharmaceuticals</subject><subject>biosimilar</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Delivery Systems</subject><subject>EPR</subject><subject>Humans</subject><subject>Medication Adherence</subject><subject>NME</subject><subject>PEG</subject><subject>PEG-biosimilar</subject><subject>PEG-linkers</subject><subject>PEGylation</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - chemistry</subject><subject>Peptides - pharmacokinetics</subject><subject>pharmacokinetics renal clearance</subject><subject>poly(ethylene glycol)</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Proteins - administration & dosage</subject><subject>Proteins - chemistry</subject><subject>Proteins - pharmacokinetics</subject><subject>putative</subject><subject>tumor-targeting</subject><issn>1742-5247</issn><issn>1744-7593</issn><issn>1743-5247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKAzEUhoMotl4ewI26cjea-8ygGym1CgVd6DrkSlNmJjWZQfr2RlsQEerqHA7f_3P4ADhD8BoxVN6gkmKGKawg5gwyXu2Bcb7RomQ12f_ecZGBcgSOUlpCSHgJ0SEYoRoTjiEdg4uX6axog_HOW3OpfFgtZGyltkPvtWzSCThwedjT7TwGbw_T18ljMX-ePU3u54WmhPUFVoRzo6paaWsqw4nWCDoKDdVYoZoj5axjtTMEO4q0wohKUztXcSJhjTQ5Bleb3lUM74NNvWh90rZpZGfDkATnNYeQ8n9BDAlDnNEMog2oY0gpWidW0bcyrgWC4kuf-KMvZ8635YNqrflJbH1l4G4D-M6F7OkjxMaIXq6bEF2UnfZJkF39t7_iCyubfqFltGIZhthlwzu--wSkDI5e</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Bailon, Pascal</creator><creator>Won, Chee-Youb</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090101</creationdate><title>PEG-modified biopharmaceuticals</title><author>Bailon, Pascal ; Won, Chee-Youb</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-2b366db89bced8d63cc10f40d4c2b1961bfef59fd32f41cb214ad9ff863a091c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>biopharmaceuticals</topic><topic>biosimilar</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Delivery Systems</topic><topic>EPR</topic><topic>Humans</topic><topic>Medication Adherence</topic><topic>NME</topic><topic>PEG</topic><topic>PEG-biosimilar</topic><topic>PEG-linkers</topic><topic>PEGylation</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - chemistry</topic><topic>Peptides - pharmacokinetics</topic><topic>pharmacokinetics renal clearance</topic><topic>poly(ethylene glycol)</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Proteins - administration & dosage</topic><topic>Proteins - chemistry</topic><topic>Proteins - pharmacokinetics</topic><topic>putative</topic><topic>tumor-targeting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bailon, Pascal</creatorcontrib><creatorcontrib>Won, Chee-Youb</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on drug delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bailon, Pascal</au><au>Won, Chee-Youb</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PEG-modified biopharmaceuticals</atitle><jtitle>Expert opinion on drug delivery</jtitle><addtitle>Expert Opin Drug Deliv</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>6</volume><issue>1</issue><spage>1</spage><epage>16</epage><pages>1-16</pages><issn>1742-5247</issn><eissn>1744-7593</eissn><eissn>1743-5247</eissn><abstract>PEGylation is a process in which one or more units of chemically activated polyethylene glycol reacts with a biomolecule, usually a protein, peptide, small molecule or oligonucleotide, creating a putative new molecular entity possessing physicochemical and physiological characteristics that are distinct from its predecessor molecules. In recent years, PEGylation has been used not only as a drug delivery technology but used also as a drug modification technology to transform existing biopharmaceuticals clinically more efficacious than before their PEGylation. PEGylation bestows several useful properties upon the native molecule, resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native molecule to achieve maximum clinical potency. In addition, PEGylation results in sustained clinical response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost. During the course of development of various pegylated protein therapeutics, several new insights have been gained. This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19236204</pmid><doi>10.1517/17425240802650568</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1742-5247 |
| ispartof | Expert opinion on drug delivery, 2009-01, Vol.6 (1), p.1-16 |
| issn | 1742-5247 1744-7593 1743-5247 |
| language | eng |
| recordid | cdi_pubmed_primary_19236204 |
| source | MEDLINE; Taylor & Francis Online; Taylor & Francis Medical Library - CRKN |
| subjects | biopharmaceuticals biosimilar Chemistry, Pharmaceutical - methods Dose-Response Relationship, Drug Drug Administration Schedule Drug Delivery Systems EPR Humans Medication Adherence NME PEG PEG-biosimilar PEG-linkers PEGylation Peptides - administration & dosage Peptides - chemistry Peptides - pharmacokinetics pharmacokinetics renal clearance poly(ethylene glycol) Polyethylene Glycols - chemistry Proteins - administration & dosage Proteins - chemistry Proteins - pharmacokinetics putative tumor-targeting |
| title | PEG-modified biopharmaceuticals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A24%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PEG-modified%20biopharmaceuticals&rft.jtitle=Expert%20opinion%20on%20drug%20delivery&rft.au=Bailon,%20Pascal&rft.date=2009-01-01&rft.volume=6&rft.issue=1&rft.spage=1&rft.epage=16&rft.pages=1-16&rft.issn=1742-5247&rft.eissn=1744-7593&rft_id=info:doi/10.1517/17425240802650568&rft_dat=%3Cproquest_pubme%3E66960046%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20351654&rft_id=info:pmid/19236204&rfr_iscdi=true |